Bowen Acquisition CORP

Bowen Acquisition Corp shareholders approved an amendment to extend the deadline for completing its initial business combination until June 14, 2026.

Bowen Acquisition Corp. received a delisting notice from Nasdaq after failing to meet listing standards and complete its business combination by the October 15, 2025 deadline.

Bowen Acquisition Corp has received a delisting determination from Nasdaq due to failure to meet multiple listing standards, including minimum shareholder count and market value requirements, leading to a trading halt.

Bowen Acquisition Corp shareholders approved an amendment to the company's articles of association, allowing the board to extend the deadline for completing its initial business combination until December 14, 2025.

Bowen Acquisition Corp received a notice from Nasdaq regarding its failure to maintain the minimum required publicly held shares, necessitating a compliance plan submission by August 25, 2025.

Bowen Acquisition Corp announced a second amendment to its merger agreement with Shenzhen Qianzhi BioTechnology Co. Ltd. and Qianzhi Group Holding (Cayman) Limited, extending the outside date for consummation to December 14, 2025.

Bowen Acquisition Corp reports significant financial losses and a Nasdaq delisting decision after failing to complete its business combination with Qianzhi.

Bowen Acquisition Corp reported a significant decline in its trust account due to high redemptions and received multiple Nasdaq delisting notices, raising substantial doubt about its ability to continue as a going concern.

Bowen Acquisition Corp reported a substantial net loss of over $2 million for the first quarter of 2025, primarily driven by costs associated with its pending business combination and a significant reduction in its trust account due to shareholder redemptions, while also facing a Nasdaq non-compliance notice for a delayed filing.

Bowen Acquisition Corp reported a net income of $2.4 million for the nine months ended September 30, 2024, primarily driven by interest earned on its trust account, while continuing its efforts to complete a business combination.

Bowen Acquisition Corp reported a net income of $1.6 million for the first six months of 2024, primarily driven by interest earned on its trust account, while actively pursuing a business combination.

Bowen Acquisition Corp reported a net income of $786,362 for the first quarter of 2024, primarily due to interest earned on its trust account.

Bowen Acquisition Corp reports a net income of $2.96 million for 2024 but expresses substantial doubt about its ability to continue as a going concern due to significant costs and working capital deficit.

Bowen Acquisition Corp's 10-K filing outlines the terms of its securities, including ordinary shares, rights, and units, and details the conditions for redemption and liquidation.

Bowen Acquisition Corp has announced a second amendment to its merger agreement with Shenzhen Qianzhi BioTechnology Co. Ltd., extending the deadline for consummation to December 14, 2025.

Harraden Circle Investments, a 10% owner of Bowen Acquisition Corp, sold 5,432 ordinary shares at a weighted-average price of $12.1174 on May 12, 2025.

Harraden Circle Investments, LLC reports the sale of 2,800 ordinary shares of Bowen Acquisition Corp at a weighted average price of $12.0353.

Harraden Circle Investments, a 10% owner and director of Bowen Acquisition Corp, sold 5,376 ordinary shares at a weighted average price of $12.0764 on May 8, 2025, leaving them with indirect ownership of 494,206 shares.

Harraden Circle Investments, a significant shareholder in Bowen Acquisition Corp (BOWN), has decreased its holdings through a series of transactions on May 7, 2025.

Harraden Circle Investments, a significant shareholder in Bowen Acquisition Corp, has reported the sale of a portion of its ordinary shares.

Bowen Acquisition Corp is seeking shareholder approval to extend its deadline for completing a business combination from June 14, 2026, to December 31, 2026, to allow more time to finalize its merger with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp. seeks shareholder approval to extend its business combination deadline to June 14, 2026, to finalize its merger with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp (BOWN) is calling an Extraordinary General Meeting on July 11, 2025, to seek shareholder approval for an extension of its business combination deadline from July 14, 2025, to December 14, 2025, as it continues efforts to consummate its previously approved merger with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp is seeking shareholder approval to extend the deadline for completing its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. by up to three months, from April 14, 2025, to July 14, 2025.

Bowen Acquisition Corp is seeking shareholder approval to extend the deadline for completing its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. from January 14, 2025, to as late as April 14, 2025.

Harraden Circle Investments and related entities, including Frederick V. Fortmiller, Jr., have disclosed a collective 16.14% beneficial ownership in Bowen Acquisition Corp's Class A Common Stock.

First Trust Merger Arbitrage Fund and related entities have filed an amended Schedule 13G, indicating they no longer hold a reportable beneficial ownership stake in Bowen Acquisition Corp as of March 31, 2025.

Harraden Circle Investments, LLC and affiliated entities, including Frederick V. Fortmiller, Jr., have reported beneficial ownership of 17.66% of Bowen Acquisition Corp's Class A Common Stock as of March 31, 2025.

AQR Capital Management, LLC and its affiliates have filed an amended Schedule 13G, indicating they no longer beneficially own any Ordinary Shares of Bowen Acquisition Corp as of March 31, 2025.

Wolverine Asset Management LLC and its affiliates have filed an amended Schedule 13G, indicating they no longer beneficially own any Ordinary Shares of Bowen Acquisition Corp.

Wolverine Asset Management LLC and affiliated entities have disclosed a 5.11% beneficial ownership stake in Bowen Acquisition Corp, holding 468,382 ordinary shares as of December 31, 2024.